### Alert
The Antimicrobial Stewardship Team recommends this drug is listed under the following category: Unrestricted.

### Indication
Directed treatment of infections caused by susceptible gram positive (including *Streptococcus* species, *Enterococcus faecalis* and *Listeria monocytogenes*) and susceptible gram negative bacteria (some strains of *Escherichia coli*, non-beta-lactamase-producing *Haemophilus influenzae*, *Neisseria meningitidis*, non-penicillinase-producing strains of *Proteus* and *Salmonella*).
Empiric treatment of suspected early onset sepsis including meningitis, with an aminoglycoside.

### Action
Bactericidal – inhibits synthesis of the bacterial cell wall. Amoxicillin is hydrolysed by beta-lactamases and therefore not effective against penicillinase-producing bacteria.

### Drug Type
Antibacterial – semi-synthetic, bactericidal aminopenicillin

### Trade Name
- Alphamox Suspension [Alphapharm], Amoxil Paediatric Drops [Aspen], Amoxil Parenteral [Aspen], Amoxil Syrup Forte Sugar Free [Aspen], Amoxicillin Sandoz [Sandoz], APO-Amoxycillin [Apotex], Bgramin [Ascent Pharma], Chemmart Amoxycillin [Apotex], Cilamox Sugar Free Syrup [Aspen Pharma], Fisamox [Aspen], Ibiaox [Willow], Maxamox [Sandoz], Ranmoxy Granules [Ranbaxy], Terry White Chemists Amoxycillin [Apotex]

### Presentation
- IV: Amoxicillin sodium 500 mg and 1 g vials
- PO: Syrup 125 mg/5 mL and 250 mg/5 mL; Paediatric drops 100 mg/mL

### Dosage / Interval
**IV**
- Treatment of standard infections: 50 mg/kg/dose.
- Treatment of meningitis: 100 mg/kg/dose.
- Dosing interval as per table below:

<table>
<thead>
<tr>
<th>Corrected Gestational Age/Postmenstrual Age</th>
<th>Postnatal Age</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 30+0 weeks</td>
<td>0–28 days</td>
<td>12 hourly</td>
</tr>
<tr>
<td>&lt; 30+0 weeks</td>
<td>29+ days</td>
<td>8 hourly</td>
</tr>
<tr>
<td>30+0–36+6 weeks</td>
<td>0–14 days</td>
<td>12 hourly</td>
</tr>
<tr>
<td>30+0–36+6 weeks</td>
<td>15+ days</td>
<td>8 hourly</td>
</tr>
<tr>
<td>37+0–44+6 weeks</td>
<td>0–7 days</td>
<td>12 hourly</td>
</tr>
<tr>
<td>37+0–44+6 weeks</td>
<td>8+ days</td>
<td>8 hourly</td>
</tr>
</tbody>
</table>

**PO**
- Treatment: 25–50 mg/kg/dose. Dose interval as follows:

<table>
<thead>
<tr>
<th>Corrected Gestational Age/Postmenstrual Age</th>
<th>Postnatal Age</th>
<th>Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>37°+–44° weeks</td>
<td>0–7 days</td>
<td>12 hourly</td>
</tr>
<tr>
<td>37°+–44° weeks</td>
<td>8+ days</td>
<td>8 hourly</td>
</tr>
</tbody>
</table>

Prophylaxis (e.g. UTI): 10–15 mg/kg/dose once a day

### Maximum Daily Dose
300 mg/kg/day

### Route
**IV**
- IM (only if IV route not possible as intramuscular route is painful)
- PO

**Preparation/Dilution**
**IV:**
- Add 4.6 mL of water for injection to the 500 mg vial for reconstitution to make 100 mg/mL solution OR
- Add 9.2 mL of water for injection to the 1 g vial for reconstitution to make 100 mg/mL solution.

**Further dilution (for 100 mg/kg/dose infusion IV):**
- Draw up 5 mL (500 mg of amoxicillin) of solution and add 5 mL sodium chloride 0.9% to make a final volume of 10mL with a concentration of 50 mg/mL.

**IM:**
- Add 2.6 mL of water for injection to the 500 mg vial for reconstitution to make 167 mg/mL solution

**PO:**
- Syrup 125 mg/5 mL: Add 87 mL water, invert the bottle and shake well. Final reconstituted
Amoxicillin (Amoxycillin)

Newborn Use Only

J.4.

suspension volume is 100 mL.
2. Syrup 250 mg/5 mL: Add 87 mL water, invert the bottle and shake well. Final reconstituted suspension volume is 100 mL.
3. Paediatric drops 100 mg/mL: Add 18 mL water, invert the bottle and shake well. Final reconstituted suspension volume is 21 mL.

Administration

IV: Infuse over 30 minutes into the proximal cannula site.
Separate from aminoglycosides by clearing the lines with a flush as penicillins inactivate them. Doses of 100 mg/kg should be diluted to 50 mg/mL and infused over 30 minutes.
IM injection: Only if IV route is not possible.
PO: The liquid preparation should be shaken well before measuring the dose. The dose may be mixed with the milk. After mixing, administer immediately.

Monitoring

Monitoring is not usually required. Follow infectious disease/microbiology advice in case of poor therapeutic response.

Contraindications

Hypersensitivity to penicillins (unlikely to be an issue in neonates).

Precautions

Hypersensitivity to cephalosporins (unlikely to be an issue in neonates).
In renal impairment, the excretion of amoxicillin will be delayed. In infants with severe renal impairment, it may be necessary to reduce the total daily dose.

Drug Interactions

IV: Aminoglycosides, including gentamicin, should not be mixed with amoxicillin when both drugs are given parenterally as inactivation of the aminoglycoside occurs. Ensure line is adequately flushed between antibiotics.
PO: No significant drug-drug interaction found for neonates on oral amoxicillin.

Adverse Reactions

Common: Diarrhoea, skin rash (erythematous maculopapular), phlebitis at the injection site, superinfection with resistant organisms during prolonged therapy
Uncommon/rare: Neurotoxicity, electrolyte disturbances e.g. hypernatraemia due to the sodium content (3.3 mmol per gram in Amoxil IV and 2.6 mmol per gram in Fisamox IV), erythema multiforme, exfoliative skin lesions, C. difficile diarrhoea, pancytopenia, raised liver enzymes. Amoxicillin may result in a false positive for glucose in the urine due to excessive amounts of urinary amoxicillin.

Compatibility

Fluids: Sodium chloride 0.9%, sterile water for injection
Y site: No information

Incompatibility

Fluids: Glucose and glucose-containing solutions, fat emulsions
Y site: Aminoglycosides, ciprofloxacin, imipenem-clastatin, midazolam, potassium chloride, sodium bicarbonate

Stability

IV: The reconstituted solution should be administered immediately; discard unused portion of the reconstituted solution.
PO: The medication mixed with milk should be administered immediately.

Storage

IV: Store below 25°C. Protect from light.
PO: Store unreconstituted powder for oral suspension at 20–25 degrees Celsius. Reconstituted suspension is stable for 14 days at room temperature or if refrigerated. Refrigeration is preferred.

Special Comments

Clearance is primarily by the renal route. Clearance increases with increasing gestational age and postmenstrual age. Serum half-life is longer in premature infants and infants younger than 7 days.

Evidence summary

Effectiveness:
There are few studies of amoxicillin in the neonatal population to study effectiveness and the majority of the information is derived from studies of ampicillin. A study in two Estonian NICUs comparing ampicillin + gentamicin versus penicillin + gentamicin in the empiric therapy of neonates at risk of early-onset sepsis showed similar effectiveness in need to change antibiotics at 72 hours and/or 7-day all-cause mortality. Subgroup analysis in ELBW neonates showed similar results, though NICU mortality was lower in the ampicillin group in < 26 weeks gestation neonates.
In an RCT of amoxicillin prophylaxis for prevention of catheter-related infections in newborns...

Neonatal Medicines Formulary Consensus Group
Amoxicillin (Amoxycillin)
Amoxicillin (Amoxycillin)

Newborn Use Only

infants with central venous catheters, bacterial contamination of the catheter tip at removal was significantly reduced in the amoxicillin group. No significant difference was found in the incidence of invasive infection. In a randomised, open-label, equivalence trial in Africa, oral amoxicillin was found to be equivalent to injectable procaine penicillin plus gentamicin in the treatment of neonates and young infants with fast breathing.

IV amoxicillin has similar properties to ampicillin and there is little to choose between the two when given by the IV route to treat susceptible organisms. Amoxicillin achieves higher serum and CSF concentrations than ampicillin. Oral amoxicillin has similar properties to ampicillin. Both the antibiotics are well absorbed when given by mouth, widely distributed in body tissues (including bronchial secretions) and rapidly excreted in the urine. Oral amoxicillin has better bioavailability but can be variable in young children. Oral medication can nearly always be used to complete any sustained course of treatment.

Pharmacokinetics:
Study of amoxicillin pharmacokinetics in preterm infants has shown that a q12h schedule in the first week achieves serum concentrations well above the MIC for major microorganisms in neonatal infections. Another study in neonates older than 1 week showed that amoxicillin clearance was related to post-conceptional age and not to postnatal age with a rapid linear increase in clearance after 34 weeks post-conceptional age.

In a study, early switching to the oral route in asymptomatic full-term newborns with early onset GBS disease maintained serum amoxicillin concentrations within the therapeutic range. The dose used in that study was 200–300 mg/kg/day in 4 divided doses. All the concentrations were in the therapeutic range with the lower dose. Another pharmacokinetic study in 6–13 days old neonates concluded that amoxicillin should be useful for oral treatment of neonatal infections caused by susceptible microorganisms in infants who are not critically ill. The dose used was 50 mg/kg twice a day.

Recommendation:
Amoxicillin can be used as a substitute for benzylpenicillin or ampicillin for suspected, early-onset, neonatal sepsis in combination with an aminoglycoside. When amoxicillin is used in combination with an aminoglycoside for the treatment of meningitis, it is recommended that the dose be doubled from 50 to 100 mg/kg/dose. This is in keeping with similar recommendations for benzylpenicillin and ampicillin based on high minimum bactericidal concentration of group B streptococci and high inocula of the organisms in neonatal meningitis. (Level of evidence 5, Grade of recommendation D).

References
8. Pullen J, Driessen M, Stolk LML, Degraeuwe PLJ, van Tiel FH, Neef C et al. Amoxicillin...
pharmacokinetics in (preterm) infants aged 10 to 52 days: Effect of postnatal age. Ther Drug Monit 2007; 29: 376-80

<table>
<thead>
<tr>
<th>Original version Date: 6/10/2016</th>
<th>Author: NMF Consensus Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Version number: 1.1</td>
<td>Current Version Date: 20/02/2017</td>
</tr>
<tr>
<td>Risk Rating: Medium</td>
<td>Due for Review: 20/02/2020</td>
</tr>
<tr>
<td>Approval by: As per Local policy</td>
<td>Approval Date:</td>
</tr>
</tbody>
</table>